Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.

× No keyword cloud information.

18 in total

1. Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: studies in psychiatric patients.

Authors: M B Bowers; R E Study
Journal: Psychopharmacology (Berl) Date: 1979-03-29 Impact factor: 4.530

2. Relationships between tryptophan in serum and CSF, and 5-hydroxyindoleacetic acid in CSF of man: effect of cirrhosis of liver and probenecid administration.

Authors: S N Young; S Lal; T L Sourkes; F Feldmuller; A Aronoff; J B Martin
Journal: J Neurol Neurosurg Psychiatry Date: 1975-04 Impact factor: 10.154

3. On the nature of brain stem disorders in severe head injured patients.

Authors: C J Vecht; T C van Woerkom; A W Teelken; J M Minderhoud
Journal: Acta Neurochir (Wien) Date: 1976 Impact factor: 2.216

4. [Monoamine metabolites and cyclic nucleotides in the cerebrospinal fluid of patients with bismuth or mercury poisoning].

Authors: H Cramer; B Renaud; M Billiard; J Mouret; R Hammers
Journal: Arch Psychiatr Nervenkr (1970) Date: 1978-12-14

Review 5. [Biochemistry of depression].

Authors: N Matussek
Journal: J Neural Transm Date: 1972 Impact factor: 3.575

Review 6. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors: R N Brogden; T M Speight; G S Avery
Journal: Drugs Date: 1971 Impact factor: 9.546

7. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.

Authors: B Johansson; B E Roos
Journal: Eur J Clin Pharmacol Date: 1971-09 Impact factor: 2.953

8. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.

Authors: G Curzon; R B Godwin-Austen; E B Tomlinson; B D Kantamaneni
Journal: J Neurol Neurosurg Psychiatry Date: 1970-02 Impact factor: 10.154

9. [Behavior of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in relation to agonized suffering (I)].

Authors: A Luna; E Villanueva; C Hernandez-Cueto; J D Luna
Journal: Z Rechtsmed Date: 1983

10. Effects of L-5-hydroxytryptophan on monoamine and amino acids turnover in the Lesch-Nyhan syndrome.

Authors: S Castells; C Chakrabarti; B G Winsberg; M Hurwic; J M Perel; W L Nyhan
Journal: J Autism Dev Disord Date: 1979-03